Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Retained Earnings (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Retained Earnings data on record, last reported at -$177.1 million in Q3 2023.

  • For Q3 2023, Retained Earnings fell 746.62% year-over-year to -$177.1 million; the TTM value through Sep 2023 reached -$177.1 million, down 746.62%, while the annual FY2022 figure was -$47.7 million, 5591.53% down from the prior year.
  • Retained Earnings reached -$177.1 million in Q3 2023 per CGEM's latest filing, down from -$1.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $203000.0 in Q2 2020 and bottomed at -$177.1 million in Q3 2023.
  • Average Retained Earnings over 4 years is -$48.4 million, with a median of -$12.3 million recorded in 2022.
  • The widest YoY moves for Retained Earnings: up 99.1% in 2021, down 214328.81% in 2021.
  • A 4-year view of Retained Earnings shows it stood at -$93.3 million in 2020, then surged by 99.1% to -$838000.0 in 2021, then plummeted by 5591.53% to -$47.7 million in 2022, then tumbled by 271.22% to -$177.1 million in 2023.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$177.1 million in Q3 2023, -$1.6 million in Q2 2023, and -$1.2 million in Q1 2023.